Science | Research
Twenty people affected by porphyria will try the drug called to significantly improve the quality of life of those affected
Twenty people affected by an ultra-rare disease will test a drug designed in the laboratories of the CIC Biogune Basque center in the United States. The preparation will not cure congenital erythropoietic porphyria, which is what this truly devastating pathology is called, but it is expected to significantly improve the lives of patients.
The
New six-monthly rate: take advantage of our discounts and subscribe for 6 months for only €25, you save 40%
Already a subscriber? Log in
Science | Research
Twenty people affected by porphyria will try the drug called to significantly improve the quality of life of those affected
Twenty people affected by an ultra-rare disease will test a drug designed in the laboratories of the CIC Biogune Basque center in the United States. The preparation will not cure congenital erythropoietic porphyria, which is what this truly devastating pathology is called, but it is expected to significantly improve the lives of patients.
The
New six-monthly rate: take advantage of our discounts and subscribe for 6 months for only €25, you save 40%
Already a subscriber? Log in
Science | Research
Twenty people affected by porphyria will try the drug called to significantly improve the quality of life of those affected
Twenty people affected by an ultra-rare disease will test a drug designed in the laboratories of the CIC Biogune Basque center in the United States. The preparation will not cure congenital erythropoietic porphyria, which is what this truly devastating pathology is called, but it is expected to significantly improve the lives of patients.
The
New six-monthly rate: take advantage of our discounts and subscribe for 6 months for only €25, you save 40%
Already a subscriber? Log in
Science | Research
Twenty people affected by porphyria will try the drug called to significantly improve the quality of life of those affected
Twenty people affected by an ultra-rare disease will test a drug designed in the laboratories of the CIC Biogune Basque center in the United States. The preparation will not cure congenital erythropoietic porphyria, which is what this truly devastating pathology is called, but it is expected to significantly improve the lives of patients.
The
New six-monthly rate: take advantage of our discounts and subscribe for 6 months for only €25, you save 40%
Already a subscriber? Log in
